Healthcare - Biotechnology - NASDAQ - US
$ 0.513
0 %
$ 1.49 M
Market Cap
-0.12
P/E
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS.[ Read More ]
The intrinsic value of one CWBR stock under the base case scenario is HIDDEN Compared to the current market price of 0.513 USD, CohBar, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CWBR
FINANCIALS
0
REVENUE
-12.4 M
OPERATING INCOME
-12.2 M
NET INCOME
-10.4 M
OPERATING CASH FLOW
11.5 M
INVESTING CASH FLOW
-140 K
FINANCING CASH FLOW
0
REVENUE
-4.43 M
OPERATING INCOME
-4.33 M
NET INCOME
-1.8 M
OPERATING CASH FLOW
2.6 M
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
CohBar, Inc.
| Current Assets | 16.2 M |
| Cash & Short-Term Investments | 15.7 M |
| Receivables | 27.5 K |
| Other Current Assets | 454 K |
| Non-Current Assets | 147 K |
| Long-Term Investments | 0 |
| PP&E | 65.5 K |
| Other Non-Current Assets | 81.7 K |
| Current Liabilities | 1.03 M |
| Accounts Payable | 180 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 854 K |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
CohBar, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 12.4 M |
| Operating Income | -12.4 M |
| Other Expenses | -213 K |
| Net Income | -12.2 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-78.02%
ROE
-73.09%
ROA
-79.39%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CohBar, Inc.
| Net Income | -12.2 M |
| Depreciation & Amortization | 99.2 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.66 M |
| Change in Working Capital | 0 |
| Others | -57.5 K |
| Free Cash Flow | -10.4 M |
Wall Street Analysts Price Targets
CohBar, Inc.
CWBR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
CohBar, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 years ago
Nov 01, 2021
|
Bought 14.4 K USD
|
GREENWOOD DAVID
Director |
+ 20000
|
0.72 USD |
|
3 years ago
Nov 01, 2021
|
Bought 14.4 K USD
|
GREENWOOD DAVID
Director |
+ 20000
|
0.72 USD |
|
3 years ago
Nov 01, 2021
|
Bought 10 K USD
|
Barzilai Nir Yacov
Director |
+ 13889
|
0.72 USD |
|
3 years ago
Nov 01, 2021
|
Bought 10 K USD
|
Barzilai Nir Yacov
Director |
+ 13889
|
0.72 USD |
|
3 years ago
Oct 28, 2021
|
Bought 96.2 K USD
|
Petkevich Misha
Director |
+ 167000
|
0.5759 USD |
|
3 years ago
Aug 18, 2021
|
Bought 22.4 K USD
|
Sarret Joseph J.
Chief Executive Officer |
+ 20000
|
1.12 USD |
|
3 years ago
Aug 11, 2021
|
Sell 20.1 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
2.01 USD |
|
3 years ago
Feb 16, 2021
|
Sell 19 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
1.9 USD |
|
3 years ago
Dec 18, 2020
|
Bought 122 K USD
|
Stern Jon Leland
Director |
+ 99861
|
1.22 USD |
|
3 years ago
Dec 18, 2020
|
Bought 108 K USD
|
Stern Jon Leland
Director |
+ 74896
|
1.44 USD |
|
3 years ago
Dec 18, 2020
|
Bought 9.14 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
+ 7490
|
1.22 USD |
|
3 years ago
Dec 18, 2020
|
Bought 8.09 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
+ 5618
|
1.44 USD |
|
4 years ago
Sep 03, 2020
|
Bought 11.2 K USD
|
Petkevich Misha
Director |
+ 11000
|
1.02 USD |
|
4 years ago
Sep 02, 2020
|
Bought 6 K USD
|
Petkevich Misha
Director |
+ 6000
|
1 USD |
|
4 years ago
Aug 28, 2020
|
Bought 9.97 K USD
|
Stern Jon Leland
Director |
+ 8169
|
1.22 USD |
|
4 years ago
Aug 28, 2020
|
Bought 8.82 K USD
|
Stern Jon Leland
Director |
+ 6127
|
1.44 USD |
|
4 years ago
Aug 10, 2020
|
Bought 100 K USD
|
Stern Jon Leland
Director |
+ 50000
|
2 USD |
|
4 years ago
Aug 28, 2020
|
Bought 250 K USD
|
Petkevich Misha
Director |
+ 204918
|
1.22 USD |
|
4 years ago
Aug 28, 2020
|
Bought 221 K USD
|
Petkevich Misha
Director |
+ 153688
|
1.44 USD |
|
4 years ago
Aug 28, 2020
|
Bought 24.4 K USD
|
GREENWOOD DAVID
Director |
+ 20000
|
1.22 USD |
|
4 years ago
Aug 28, 2020
|
Bought 21.6 K USD
|
GREENWOOD DAVID
Director |
+ 15000
|
1.44 USD |
|
4 years ago
Aug 28, 2020
|
Bought 10 K USD
|
FITZGERALD ALBION
Director |
+ 8196
|
1.22 USD |
|
4 years ago
Aug 28, 2020
|
Bought 8.85 K USD
|
FITZGERALD ALBION
Director |
+ 6147
|
1.44 USD |
|
4 years ago
Aug 10, 2020
|
Bought 7.5 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
+ 3750
|
2 USD |
|
4 years ago
Aug 06, 2020
|
Sell 19 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
1.9 USD |
|
4 years ago
Jun 15, 2020
|
Sell 24.1 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
2.41 USD |
|
4 years ago
May 15, 2020
|
Sell 25.6 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
2.56 USD |
|
4 years ago
Apr 22, 2020
|
Sell 8.93 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 4700
|
1.9 USD |
|
4 years ago
Feb 24, 2020
|
Sell 9.75 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
1.95 USD |
|
4 years ago
Feb 21, 2020
|
Sell 19 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
1.9 USD |
|
4 years ago
Feb 03, 2020
|
Sell 10.7 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
2.14 USD |
|
4 years ago
Jan 27, 2020
|
Sell 12.5 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
2.51 USD |
|
4 years ago
Jan 21, 2020
|
Sell 11 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
2.19 USD |
|
4 years ago
Jan 15, 2020
|
Sell 19.1 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
1.907 USD |
|
4 years ago
Jan 14, 2020
|
Sell 15.3 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 7981
|
1.912 USD |
|
4 years ago
Jan 14, 2020
|
Sell 9.8 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
1.96 USD |
|
4 years ago
Dec 16, 2019
|
Sell 3.84 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 2019
|
1.9 USD |
|
5 years ago
Nov 18, 2019
|
Sell 9.75 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
1.95 USD |
|
5 years ago
Nov 15, 2019
|
Sell 19.2 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 10000
|
1.9201 USD |
|
5 years ago
Nov 11, 2019
|
Sell 9.75 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
1.95 USD |
|
5 years ago
Nov 04, 2019
|
Sell 11.2 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
2.25 USD |
|
5 years ago
Oct 31, 2019
|
Sell 9.75 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
- 5000
|
1.95 USD |
|
5 years ago
Oct 30, 2019
|
Sell 17.3 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 9095
|
1.9 USD |
|
5 years ago
Oct 29, 2019
|
Sell 1.52 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
- 802
|
1.9 USD |
|
6 years ago
Apr 13, 2018
|
Bought 42.4 K USD
|
Stern Jon Leland
Chief Operating Officer |
+ 8000
|
5.3 USD |
|
6 years ago
Mar 29, 2018
|
Bought 106 K USD
|
Stern Jon Leland
Chief Operating Officer |
+ 20000
|
5.3 USD |
|
6 years ago
Mar 29, 2018
|
Bought 398 K USD
|
FITZGERALD ALBION
Director |
+ 75000
|
5.3 USD |
|
6 years ago
Mar 29, 2018
|
Bought 7.95 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
+ 1500
|
5.3 USD |
|
6 years ago
Mar 29, 2018
|
Bought 10.6 K USD
|
ALLEN SIMON
Chief Executive Officer |
+ 2000
|
5.3 USD |
|
7 years ago
Jan 31, 2017
|
Bought 460 USD
|
ALLEN SIMON
Chief Executive Officer |
+ 200
|
2.3 USD |
|
7 years ago
Jan 31, 2017
|
Bought 335 USD
|
ALLEN SIMON
Chief Executive Officer |
+ 135
|
2.48 USD |
|
7 years ago
Jan 31, 2017
|
Sell 210 USD
|
ALLEN SIMON
Chief Executive Officer |
- 100
|
2.1 USD |
|
7 years ago
Jan 31, 2017
|
Sell 66.1 USD
|
ALLEN SIMON
Chief Executive Officer |
- 35
|
1.89 USD |
|
9 years ago
Nov 19, 2015
|
Bought 290 USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
+ 250
|
1.16 USD |
|
9 years ago
Jun 01, 2015
|
Bought 4.7 K USD
|
Barzilai Nir Yacov
director, 10 percent owner: |
+ 5000
|
0.94 USD |
|
9 years ago
Jun 01, 2015
|
Bought 5.75 K USD
|
Cohen Pinchas
director, 10 percent owner: |
+ 5000
|
1.15 USD |
|
9 years ago
May 26, 2015
|
Bought 4.36 K USD
|
FITZGERALD ALBION
Director |
+ 4500
|
0.97 USD |
|
9 years ago
May 26, 2015
|
Bought 735 USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
+ 750
|
0.98 USD |
|
9 years ago
May 22, 2015
|
Bought 2.91 K USD
|
FITZGERALD ALBION
Director |
+ 3000
|
0.97 USD |
|
9 years ago
May 22, 2015
|
Bought 10 K USD
|
Cundy Kenneth C
Chief Scientific Officer |
+ 10000
|
1 USD |
|
9 years ago
May 20, 2015
|
Bought 4.9 K USD
|
Stern Jon Leland
Chief Executive Officer |
+ 5000
|
0.98 USD |
|
9 years ago
May 21, 2015
|
Bought 5.7 K USD
|
FITZGERALD ALBION
Director |
+ 6000
|
0.95 USD |
|
9 years ago
May 20, 2015
|
Bought 4.36 K USD
|
FITZGERALD ALBION
Director |
+ 4500
|
0.97 USD |
|
9 years ago
May 22, 2015
|
Bought 1.9 K USD
|
Biunno Jeffrey Francis
CFO, Treasurer and Secretary |
+ 2000
|
0.95 USD |
|
9 years ago
Jan 06, 2015
|
Bought 150 K USD
|
Stern Jon Leland
Chief Executive Officer |
+ 150000
|
1 USD |
|
9 years ago
Jan 06, 2015
|
Bought 150 K USD
|
Stern Jon Leland
Chief Executive Officer |
+ 75000
|
2 USD |
|
9 years ago
Jan 06, 2015
|
Bought 500 K USD
|
FITZGERALD ALBION
Director |
+ 500000
|
1 USD |
|
9 years ago
Jan 06, 2015
|
Bought 500 K USD
|
FITZGERALD ALBION
Director |
+ 250000
|
2 USD |
7. News
CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
MENLO PARK, Calif.--(BUSINESS WIRE)--On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a “public shell,” and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing.
businesswire.com
- 11 months ago
COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of CohBar, Inc. (the “Company”) (NasdaqCM: CWBR) with Morphogenesis, Inc. pursuant to which CohBar shareholders will end up owning approximately 15% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
businesswire.com
- 1 year ago
CohBar Reports Second Quarter 2023 Financial Results
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023.
globenewswire.com
- 1 year ago
Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.
MILWAUKEE, May 24, 2023 /PRNewswire/ — Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc. Click here to learn how to join the action https://www.ademilaw.com/case/cohbar-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. CohBar public stockholders […]...
headlinesoftoday.com
- 1 year ago
Why Is CohBar (CWBR) Stock Up 130% Today?
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.
investorplace.com
- 1 year ago
CWBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of CohBar, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of CohBar, Inc. (NASDAQ: CWBR) and Morphogenesis, Inc. is fair to CohBar shareholders. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether CohBar and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for CohBar shareholders; and (2) disclose all material information necessary for CohBar shareholders to adequately assess and value the merger consideration. On behalf of CohBar shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
businesswire.com
- 1 year ago
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
globenewswire.com
- 2 years ago
Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 2 years ago
7 Nasdaq Stocks to Sell Before They Die
As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500.
investorplace.com
- 2 years ago
CohBar (CWBR) Stock: 1-For-30 Reverse Split Goes Into Effect
A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.
pulse2.com
- 2 years ago
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022.
globenewswire.com
- 2 years ago
CohBar, Inc. (CWBR) CEO Joe Sarret on Q2 2022 Results - Earnings Call Transcript
CohBar, Inc. (NASDAQ:CWBR ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is Ryan, and I will be your conference operator for today.
seekingalpha.com
- 2 years ago
8. Profile Summary
CohBar, Inc. CWBR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.49 M
Dividend Yield
0.00%
Description
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Contact
1455 Adams Drive, Menlo Park, CA, 94025
https://www.cohbar.com
IPO Date
Dec. 15, 2017
Employees
9
Officers
Dr. John M. Amatruda M.D., Ph.D.
Co-Founder
Ms. Jordyn Tarazi
Director of Investor Relations
Dr. Nir Yacov Barzilai M.D.
Founder & Member of Scientific Advisory Board
Dr. Pinchas Cohen Dean, M.D., Ph.D.
Founder & Member of Scientific Advisory Board